Research
Our program is also actively involved in developing new therapies, including clinical trials sponsored by the National Institutes of Health. To learn more, please call 312.996.5680 or email our research coordinators, Lani Krauz and Taif Hassan.
Below is a list of our current ongoing clinical trials.
| SPONSOR | TITLE | CLINICAL TRIAL ID |
|---|---|---|
| Afimmune | DS102A-10-RD2: An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease | NCT05861453 |
| CSL Behring | CSL889_2001: A Phase 2 / Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis | NCT06699849 |
| Fulcrum | 6058-SCD-101: A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects with Sickle Cell Disease (SCD) | NCT05169580 |
| Novo Nordisk | Hibiscus 2: A research study to evaluate how well etavopivat works in people with sickle cell disease | NCT06612268 |
| Pfizer | C5351004: A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants With Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants With Sickle Cell Disease | NCT05431088 |
